kabutan

Astellas Pharma, Last Fiscal Year's Net Income Unexpectedly Increases, 2.6 times Increase in Net Income for The Current Fiscal Year, Dividend Raised by 4 yen

Fri Apr 25, 2025 3:30 pm JST Earnings

4503 Astellas Pharma Inc. 【IFRS】

Earnings Report

Astellas Pharma Inc. <4503> [TSE Prime] announced its financial results (based on IFRS) after the market closed on April 25th (15:30). The consolidated net income for the fiscal year ending March 2025 increased 3.0 times that of the previous period to 50.7 billion yen exceeding the previous forecast of 14 billion yen and resulted in an increase in profit, a complete reversal from the forecast for a decline in profit. In the fiscal year ending March 2026, the profit is expected to surge 2.6 times the previous term, reaching 130 billion yen. This will be the fifth consecutive term of revenue growth.

At the same time, the company has decided to increase the dividend this fiscal year to 78 yen, an increase of 4 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated net income/loss turned to a profit of 74.8 billion yen (compared to a loss of 33.2 billion yen in the same period last year). The operating profit/loss margin drastically improved from -11.7% in the same period last year to 13.8%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 1,518,619 133,029 132,361 98,714 54.2 60 Apr 27, 2023 IFRS
Mar, 2024 1,603,672 25,518 24,969 17,045 9.5 70 Apr 25, 2024 IFRS
Mar, 2025 1,912,323 41,039 31,237 50,747 28.4 74 Apr 25, 2025 IFRS
YoY +19.2% +60.8% +25.1% +197.7% +198.1%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 1,900,000 11,000 1,000 14,000 7.8 74 Jan 24, 2025 IFRS
Mar, 2025 Results 1,912,323 41,039 31,237 50,747 28.4 74 Apr 25, 2025 IFRS
Revision Rate +0.6% +273.1% +3,023.7% +262.5% +262.5%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 935,621 93,710 89,042 73,511 41.1 37 Oct 30, 2024 IFRS
Apr - Sep, 2025 Guidance ー ー ー ー － 39 Apr 25, 2025 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 1,603,672 25,518 24,969 17,045 9.5 70 Apr 25, 2024 IFRS
Mar, 2025 1,912,323 41,039 31,237 50,747 28.4 74 Apr 25, 2025 IFRS
Mar, 2026 Guidance 1,930,000 160,000 150,000 130,000 72.6 78 Apr 25, 2025 IFRS
YoY +0.9% +289.9% +380.2% +156.2% +156.1%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 414,602 -48,601 -48,661 -33,278 -18.6 -11.7 Apr 25, 2024 IFRS
Apr - Jun, 2024 473,124 50,657 50,495 37,603 21.0 10.7 Aug 1, 2024 IFRS
Jul - Sep, 2024 462,497 43,053 38,547 35,908 20.1 9.3 Oct 30, 2024 IFRS
Oct - Dec, 2024 517,408 -116,191 -118,359 -97,660 -54.6 -22.5 Feb 4, 2025 IFRS
Jan - Mar, 2025 459,294 63,520 60,554 74,896 41.8 13.8 Apr 25, 2025 IFRS
YoY +10.8% － － － －

Related Articles